Literature DB >> 33570492

The allosteric modulation of complement C5 by knob domain peptides.

Alex Macpherson1,2, Maisem Laabei2, Zainab Ahdash1, Melissa A Graewert3, James R Birtley1, Monika-Sarah Ed Schulze1, Susan Crennell2, Sarah A Robinson4, Ben Holmes1, Vladas Oleinikovas1, Per H Nilsson1,5,6, James Snowden1, Victoria Ellis1, Tom Eirik Mollnes6,7,8, Charlotte M Deane4, Dmitri Svergun3, Alastair Dg Lawson1, Jean Mh van den Elsen2,9.   

Abstract

Bovines have evolved a subset of antibodies with ultra-long heavy chain complementarity determining regions that harbour cysteine-rich knob domains. To produce high-affinity peptides, we previously isolated autonomous 3-6 kDa knob domains from bovine antibodies. Here, we show that binding of four knob domain peptides elicits a range of effects on the clinically validated drug target complement C5. Allosteric mechanisms predominated, with one peptide selectively inhibiting C5 cleavage by the alternative pathway C5 convertase, revealing a targetable mechanistic difference between the classical and alternative pathway C5 convertases. Taking a hybrid biophysical approach, we present C5-knob domain co-crystal structures and, by solution methods, observed allosteric effects propagating >50 Å from the binding sites. This study expands the therapeutic scope of C5, presents new inhibitors, and introduces knob domains as new, low molecular weight antibody fragments, with therapeutic potential.
© 2021, Macpherson et al.

Entities:  

Keywords:  bovine immunoglobulin; complement C5; human; immunology; inflammation; knob-domain peptides; molecular biophysics; structural biology

Mesh:

Substances:

Year:  2021        PMID: 33570492      PMCID: PMC7972453          DOI: 10.7554/eLife.63586

Source DB:  PubMed          Journal:  Elife        ISSN: 2050-084X            Impact factor:   8.140


  60 in total

1.  Structure of and influence of a tick complement inhibitor on human complement component 5.

Authors:  Folmer Fredslund; Nick S Laursen; Pietro Roversi; Lasse Jenner; Cristiano L P Oliveira; Jan S Pedersen; Miles A Nunn; Susan M Lea; Richard Discipio; Lars Sottrup-Jensen; Gregers R Andersen
Journal:  Nat Immunol       Date:  2008-06-08       Impact factor: 25.606

2.  The cobra venom factor-dependent C3 convertase of human complement. A kinetic and thermodynamic analysis of a protease acting on its natural high molecular weight substrate.

Authors:  C W Vogel; H J Müller-Eberhard
Journal:  J Biol Chem       Date:  1982-07-25       Impact factor: 5.157

3.  Crystal Structures of Protein-Bound Cyclic Peptides.

Authors:  Alpeshkumar K Malde; Timothy A Hill; Abishek Iyer; David P Fairlie
Journal:  Chem Rev       Date:  2019-05-02       Impact factor: 60.622

4.  Structural Basis for Eculizumab-Mediated Inhibition of the Complement Terminal Pathway.

Authors:  Janus Asbjørn Schatz-Jakobsen; Yuchun Zhang; Krista Johnson; Alyssa Neill; Douglas Sheridan; Gregers Rom Andersen
Journal:  J Immunol       Date:  2016-05-18       Impact factor: 5.422

5.  Versatile sample environments and automation for biological solution X-ray scattering experiments at the P12 beamline (PETRA III, DESY).

Authors:  Clement E Blanchet; Alessandro Spilotros; Frank Schwemmer; Melissa A Graewert; Alexey Kikhney; Cy M Jeffries; Daniel Franke; Daniel Mark; Roland Zengerle; Florent Cipriani; Stefan Fiedler; Manfred Roessle; Dmitri I Svergun
Journal:  J Appl Crystallogr       Date:  2015-03-12       Impact factor: 3.304

6.  Exploring Ligand Stability in Protein Crystal Structures Using Binding Pose Metadynamics.

Authors:  Lucia Fusani; David S Palmer; Don O Somers; Ian D Wall
Journal:  J Chem Inf Model       Date:  2020-01-22       Impact factor: 4.956

7.  Ab-Ligity: identifying sequence-dissimilar antibodies that bind to the same epitope.

Authors:  Wing Ki Wong; Sarah A Robinson; Alexander Bujotzek; Guy Georges; Alan P Lewis; Jiye Shi; James Snowden; Bruck Taddese; Charlotte M Deane
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

8.  The rational design of affinity-attenuated OmCI for the purification of complement C5.

Authors:  Alex Macpherson; Xiaofeng Liu; Neesha Dedi; Jeffery Kennedy; Bruce Carrington; Oliver Durrant; Sam Heywood; Jean van den Elsen; Alastair D G Lawson
Journal:  J Biol Chem       Date:  2018-07-20       Impact factor: 5.157

9.  Structural basis of broad HIV neutralization by a vaccine-induced cow antibody.

Authors:  Robyn L Stanfield; Zachary T Berndsen; Ruiqi Huang; Devin Sok; Gabrielle Warner; Jonathan L Torres; Dennis R Burton; Andrew B Ward; Ian A Wilson; Vaughn V Smider
Journal:  Sci Adv       Date:  2020-05-27       Impact factor: 14.136

10.  Complement Inhibition with the C5 Blocker LFG316 in Severe COVID-19.

Authors:  Wioleta M Zelek; Jade Cole; Mark J Ponsford; Richard A Harrison; Ben E Schroeder; Nicholas Webb; Stephen Jolles; Christopher Fegan; Matt Morgan; Matt P Wise; B Paul Morgan
Journal:  Am J Respir Crit Care Med       Date:  2020-11-01       Impact factor: 30.528

View more
  3 in total

1.  The proximity of the N- and C- termini of bovine knob domains enable engineering of target specificity into polypeptide chains.

Authors:  Alice Hawkins; Callum Joyce; Kevin Brady; Adam Hold; Alan Smith; Michael Knight; Conor Howard; Jean van den Elsen; Alastair D G Lawson; Alex Macpherson
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 6.440

2.  Milking the Cow: Cattle-Derived Chimeric Ultralong CDR-H3 Antibodies and Their Engineered CDR-H3-Only Knobbody Counterparts Targeting Epidermal Growth Factor Receptor Elicit Potent NK Cell-Mediated Cytotoxicity.

Authors:  Lukas Pekar; Daniel Klewinghaus; Paul Arras; Stefania C Carrara; Julia Harwardt; Simon Krah; Desislava Yanakieva; Lars Toleikis; Vaughn V Smider; Harald Kolmar; Stefan Zielonka
Journal:  Front Immunol       Date:  2021-10-25       Impact factor: 7.561

3.  Multifaceted Activities of Seven Nanobodies against Complement C4b.

Authors:  Karla I De la O Becerra; Wout Oosterheert; Ramon M van den Bos; Katerina T Xenaki; Joseph H Lorent; Maartje Ruyken; Arie Schouten; Suzan H M Rooijakkers; Paul M P van Bergen En Henegouwen; Piet Gros
Journal:  J Immunol       Date:  2022-04-15       Impact factor: 5.426

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.